Major drugmakers, the British government, and a top Alzheimer’s research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment – or even a cure for the mind-robbing disease within a decade. The new Dementia Discovery Fund will function like a venture capital fund. It will identify promising laboratory discoveries in Alzheimer’s disease and other forms of dementia, then distribute money to cover costs for the steps needed to prepare for and then begin the first tests in patients. Dementia affects around 47 million people, and that number is expected to double by 2030, and more than triple by 2050. Initial financing for the groundbreaking project has been committed by the British government, the charity Alzheimer’s Research UK and five companies: Johnson and Johnson, Eli Lilly, Pfizer, and Biogen Idec in the U.S., and Britain’s GlaxoSmithKline.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
